Skip to main content
. 2020 Dec 21;15(12):e0244349. doi: 10.1371/journal.pone.0244349

Fig 3. Stratified analysis of relationships between previous treatment with RAAS blockers and COVID-19, according to sex, age > 60 years, hypertension, diabetes, and renal failure (eGFR < 60 mL/min).

Fig 3

ACEIs indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II type 1 receptor blockers; COVID-19: coronavirus disease 2019; eGFR, estimated glomerular filtration rate calculated by the Modification of Diet in Renal Disease study method; RAAS, renin-angiotensin-aldosterone system.